drugset / Trial / NCT06469138

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

NCT06469138

Phase 1 Completed 6 enrolled BerGenBio ASA
NaSingle-groupOpen-labelTreatment

Summary

The aims of this Study were to determine: * How much of the Study Drug (bemcentinib) ends up in urine and faeces * How much of the Study Drug and its breakdown products get into the bloodstream * The breakdown products (metabolites) of the Study Drug * The safety of the Study Drug and any side effects that might be associated with it.

Timeline

Start
2022-08-02
Primary completion
2022-09-23
Completion
2022-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemcentinib Small molecule 200 mg Oral